Conference Proceedings

Biomarker analysis of the phase III IPATential150 trial of first-line ipatasertib (Ipat) plus abiraterone (Abi) in metastatic castration-resistant prostate cancer (mCRPC)

Zhen Shi, Christopher Sweeney, Sergio Bracarda, Cora N Sternberg, Kim N Chi, David Olmos, Shahneen Kaur Sandhu, Christophe Massard, Nobuaki Matsubara, Marie-Laurence Harle-Yge, Malgorzata Nowicka, Matthew Wongchenko, Johann S De Bono

JOURNAL OF CLINICAL ONCOLOGY | AMER SOC CLINICAL ONCOLOGY | Published : 2020

Grants

Funding Acknowledgements

F. Hoffmann-La Roche Ltd